The 'Grippol Plus' vaccine is given to children and pregnant women to prevent them falling ill with flu, and is sold throughout the Commonwealth of Independent States and in some EU countries, for example Slovakia.
After extensive testing in the Islamic Republic, doctors there decided that the vaccine would be a welcome addition to their medical arsenal, and Iranian manufacturers of pharmaceuticals asked Petrovax for the right to produce the vaccine, Petrovax President Yelena Arhangelskaya told Sputnik.
"We made the first delivery of 'Grippol Plus' to Iran in 2015 and got positive reviews from Iran's Ministry of Health and the relevant medical specialists. After that we got an offer from Iranian company Sobhan Recombinant Protein for the transfer of technology to produce 'Grippol Plus.'"
"We accepted the offer, and according to the terms of our agreement over the next three years there will be a gradual transfer of technology across the production cycle of the vaccine," Arhangelskaya explained.
"This allows Iran to increase the number of people who are vaccinated and gives the opportunity to add the vaccine to the national immunization program, as is practiced in many countries."
"SRP will transfer the technology to produce a hepatitis B vaccine in Russia, and so Petrovax will complete a similar process to acquire the production technology," Arhangelskaya said.
"Another agreement has been signed with CinnaGen to transfer the technology to produce and license drugs to treat rheumatoid arthritis. This company has a wide range of medicine and if our first project proves successful we will definitely expand our cooperation."
